10 year coronary heart disease (CHD) risk evaluation and its treatment pattern analysis in postmenopausal early breast cancer (EBC) patients taking aromatase inhibitors (AI)

Study identifier:NIS-OKR-DUM-2009/1

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

10-year CHD risk evaluation and its treatment pattern analysis in postmenopausal early breast cancer patients taking aromatase inhibitors

Medical condition

Breast Cancer

Phase

-

Healthy volunteers

No

Study drug

-

Sex

Female

Actual Enrollment

1114

Study type

Observational

Age

50 Years +

Date

Study Start Date: 01 May 2009
Primary Completion Date: 01 Mar 2010
Study Completion Date: 01 Mar 2010

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria